



June 12, 2023

BSE Ltd.
Phiroze Jeejebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: USFDA inspection of Company's manufacturing facility – T20 at Panoli, Gujarat

We wish to inform the exchange that the Company's formulations manufacturing facility- T20 located at Plot No. 4, GIDC, Panoli, Gujarat was inspected by the USFDA. The inspection was conducted from June 5, 2023 to June 9, 2023.

At the end of the inspection, the facility received "No Observations" and thus NO Form 483 was issued.

The Company remains committed to producing quality products, embedding a quality culture across the organization and continuously investing in systems, processes & training of its employees so that it can maintain the highest standards of quality and compliance for all its markets.

We request you to take the above announcement on record.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis
Vice President-Secretarial
& Company Secretary

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road,
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,
CIN: L24390MH1976PLC019380
Energy IT Park, Unit A, 8th Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500
secretarial@jbpharma.com